Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers.

Campbell E, Kennedy F, Russell A, Smithson WH, Parsons L, Morrison PJ, Liggan B, Irwin B, Delanty N, Hunt SJ, Craig J, Morrow J.

J Neurol Neurosurg Psychiatry. 2014 Sep;85(9):1029-34. doi: 10.1136/jnnp-2013-306318. Epub 2014 Jan 20.

PMID:
24444855
2.

Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.

Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, Perucca E, Vajda F; EURAP study group.

Lancet Neurol. 2011 Jul;10(7):609-17. doi: 10.1016/S1474-4422(11)70107-7. Epub 2011 Jun 5.

PMID:
21652013
3.

Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register.

Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, Irwin B, McGivern RC, Morrison PJ, Craig J.

J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):193-8. Epub 2005 Sep 12.

4.

Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers.

Mawhinney E, Craig J, Morrow J, Russell A, Smithson WH, Parsons L, Morrison PJ, Liggan B, Irwin B, Delanty N, Hunt SJ.

Neurology. 2013 Jan 22;80(4):400-5. doi: 10.1212/WNL.0b013e31827f0874. Epub 2013 Jan 9. Erratum in: Neurology. 2013 Feb 12;80(7):691.

PMID:
23303847
5.
6.

Final results from 18 years of the International Lamotrigine Pregnancy Registry.

Cunnington MC, Weil JG, Messenheimer JA, Ferber S, Yerby M, Tennis P.

Neurology. 2011 May 24;76(21):1817-23. doi: 10.1212/WNL.0b013e31821ccd18.

PMID:
21606453
7.

Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs.

Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW; NEAD Study Group.

N Engl J Med. 2009 Apr 16;360(16):1597-605. doi: 10.1056/NEJMoa0803531.

8.

Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations.

Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S.

Arch Neurol. 2011 Oct;68(10):1275-81. doi: 10.1001/archneurol.2011.133. Epub 2011 Jun 13.

PMID:
21670385
9.

Behavioral outcomes in children exposed prenatally to lamotrigine, valproate, or carbamazepine.

Deshmukh U, Adams J, Macklin EA, Dhillon R, McCarthy KD, Dworetzky B, Klein A, Holmes LB.

Neurotoxicol Teratol. 2016 Mar-Apr;54:5-14. doi: 10.1016/j.ntt.2016.01.001. Epub 2016 Jan 12.

10.

Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: Results from a pregnancy registry in South India.

Thomas SV, Jose M, Divakaran S, Sankara Sarma P.

Epilepsia. 2017 Feb;58(2):274-281. doi: 10.1111/epi.13632. Epub 2017 Jan 13.

PMID:
28084641
11.

In utero antiepileptic drug exposure: fetal death and malformations.

Meador KJ, Baker GA, Finnell RH, Kalayjian LA, Liporace JD, Loring DW, Mawer G, Pennell PB, Smith JC, Wolff MC; NEAD Study Group.

Neurology. 2006 Aug 8;67(3):407-12.

12.

Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study.

Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, Sabers A, Thomas SV, Vajda F; EURAP Study Group.

Neurology. 2015 Sep 8;85(10):866-72. doi: 10.1212/WNL.0000000000001772. Epub 2015 Jun 17.

PMID:
26085607
13.

Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.

Weston J, Bromley R, Jackson CF, Adab N, Clayton-Smith J, Greenhalgh J, Hounsome J, McKay AJ, Tudur Smith C, Marson AG.

Cochrane Database Syst Rev. 2016 Nov 7;11:CD010224. Review.

PMID:
27819746
14.

Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy.

Tomson T, Perucca E, Battino D.

Epilepsia. 2004 Oct;45(10):1171-5.

15.

Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.

Nevitt SJ, Sudell M, Weston J, Tudur Smith C, Marson AG.

Cochrane Database Syst Rev. 2017 Jun 29;6:CD011412. doi: 10.1002/14651858.CD011412.pub2. Review.

PMID:
28661008
16.

Maternal valproate dosage and foetal malformations.

Vajda FJ, Eadie MJ.

Acta Neurol Scand. 2005 Sep;112(3):137-43.

PMID:
16097954
17.

Valproate and the risk for congenital malformations: Is formulation and dosage regime important?

Mawhinney E, Campbell J, Craig J, Russell A, Smithson W, Parsons L, Robertson I, Irwin B, Morrison P, Liggan B, Delanty N, Hunt S, Morrow J.

Seizure. 2012 Apr;21(3):215-8. doi: 10.1016/j.seizure.2012.01.005. Epub 2012 Feb 23.

18.

A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy.

McVearry KM, Gaillard WD, VanMeter J, Meador KJ.

Epilepsy Behav. 2009 Dec;16(4):609-16. doi: 10.1016/j.yebeh.2009.09.024. Epub 2009 Nov 4.

19.

Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study.

Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW; NEAD Study Group.

Lancet Neurol. 2013 Mar;12(3):244-52. doi: 10.1016/S1474-4422(12)70323-X. Epub 2013 Jan 23.

20.

Antiepileptic drug combinations not involving valproate and the risk of fetal malformations.

Vajda FJ, O'Brien TJ, Lander CM, Graham J, Eadie MJ.

Epilepsia. 2016 Jul;57(7):1048-52. doi: 10.1111/epi.13415. Epub 2016 Jun 5.

Supplemental Content

Support Center